Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.
Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.
This report offers an overview of the market trends, drivers, and barriers with respect to the China Glioblastoma Multiforme Therapeutics market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Glioblastoma Multiforme Therapeutics market. Detailed analysis of key players, along with key growth strategies adopted by Glioblastoma Multiforme Therapeutics industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Bristol-Myers Squibb
Merck
F Hoffmann-La Roche
Arbor Pharmaceuticals
Eisai
By Type:
Temozolomide
Bevacozumab
Carmustine
By End-User:
Hospitals
Clinics
Others
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Glioblastoma Multiforme Therapeutics Market
-
1.3 Market Segment by Type
-
1.3.1 China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Temozolomide from 2016 to 2027
-
1.3.2 China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Bevacozumab from 2016 to 2027
-
1.3.3 China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Carmustine from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Hospitals from 2016 to 2027
-
1.4.2 China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Clinics from 2016 to 2027
-
1.4.3 China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Others from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Glioblastoma Multiforme Therapeutics Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Glioblastoma Multiforme Therapeutics by Major Types
-
3.4.1 Market Size and Growth Rate of Temozolomide
-
3.4.2 Market Size and Growth Rate of Bevacozumab
-
3.4.3 Market Size and Growth Rate of Carmustine
4 Segmentation of Glioblastoma Multiforme Therapeutics Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Glioblastoma Multiforme Therapeutics by Major End-Users
-
4.4.1 Market Size and Growth Rate of Glioblastoma Multiforme Therapeutics in Hospitals
-
4.4.2 Market Size and Growth Rate of Glioblastoma Multiforme Therapeutics in Clinics
-
4.4.3 Market Size and Growth Rate of Glioblastoma Multiforme Therapeutics in Others
5 Market Analysis by Regions
-
5.1 China Glioblastoma Multiforme Therapeutics Production Analysis by Regions
-
5.2 China Glioblastoma Multiforme Therapeutics Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Glioblastoma Multiforme Therapeutics Landscape Analysis
-
6.1 North China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
6.2 North China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
7 Central China Glioblastoma Multiforme Therapeutics Landscape Analysis
-
7.1 Central China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
7.2 Central China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
8 South China Glioblastoma Multiforme Therapeutics Landscape Analysis
-
8.1 South China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
8.2 South China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
9 East China Glioblastoma Multiforme Therapeutics Landscape Analysis
-
9.1 East China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
9.2 East China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
10 Northeast China Glioblastoma Multiforme Therapeutics Landscape Analysis
-
10.1 Northeast China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
10.2 Northeast China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
11 Southwest China Glioblastoma Multiforme Therapeutics Landscape Analysis
-
11.1 Southwest China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
11.2 Southwest China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
12 Northwest China Glioblastoma Multiforme Therapeutics Landscape Analysis
-
12.1 Northwest China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
12.2 Northwest China Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 Bristol-Myers Squibb
-
13.1.1 Bristol-Myers Squibb Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 Merck
-
13.2.1 Merck Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 F Hoffmann-La Roche
-
13.3.1 F Hoffmann-La Roche Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
-
13.4 Arbor Pharmaceuticals
-
13.4.1 Arbor Pharmaceuticals Company Profile and Recent Development
-
13.4.2 Market Performance
-
13.4.3 Product and Service Introduction
-
13.5 Eisai
-
13.5.1 Eisai Company Profile and Recent Development
-
13.5.2 Market Performance
-
13.5.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Temozolomide from 2016 to 2027
-
Figure China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Bevacozumab from 2016 to 2027
-
Figure China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Carmustine from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Hospitals from 2016 to 2027
-
Figure China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Clinics from 2016 to 2027
-
Figure China Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Others from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Glioblastoma Multiforme Therapeutics Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Glioblastoma Multiforme Therapeutics
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Glioblastoma Multiforme Therapeutics by Different Types from 2016 to 2027
-
Table Consumption Share of Glioblastoma Multiforme Therapeutics by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Temozolomide
-
Figure Market Size and Growth Rate of Bevacozumab
-
Figure Market Size and Growth Rate of Carmustine
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Glioblastoma Multiforme Therapeutics by Different End-Users from 2016 to 2027
-
Table Consumption Share of Glioblastoma Multiforme Therapeutics by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hospitals
-
Figure Market Size and Growth Rate of Clinics
-
Figure Market Size and Growth Rate of Others
-
Table China Glioblastoma Multiforme Therapeutics Production by Regions
-
Table China Glioblastoma Multiforme Therapeutics Production Share by Regions
-
Figure China Glioblastoma Multiforme Therapeutics Production Share by Regions in 2016
-
Figure China Glioblastoma Multiforme Therapeutics Production Share by Regions in 2021
-
Figure China Glioblastoma Multiforme Therapeutics Production Share by Regions in 2027
-
Table China Glioblastoma Multiforme Therapeutics Consumption by Regions
-
Table China Glioblastoma Multiforme Therapeutics Consumption Share by Regions
-
Figure China Glioblastoma Multiforme Therapeutics Consumption Share by Regions in 2016
-
Figure China Glioblastoma Multiforme Therapeutics Consumption Share by Regions in 2021
-
Figure China Glioblastoma Multiforme Therapeutics Consumption Share by Regions in 2027
-
Table North China Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table North China Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure North China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure North China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure North China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table North China Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table North China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure North China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure North China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure North China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table Central China Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table Central China Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure Central China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure Central China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure Central China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table Central China Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table Central China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure Central China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure Central China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table South China Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table South China Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure South China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure South China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure South China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table South China Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table South China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure South China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure South China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure South China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table East China Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table East China Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure East China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure East China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure East China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table East China Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table East China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure East China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure East China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure East China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table Northeast China Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table Northeast China Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure Northeast China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure Northeast China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table Northeast China Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table Northeast China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure Northeast China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure Northeast China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table Southwest China Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table Southwest China Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure Southwest China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure Southwest China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table Southwest China Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table Southwest China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure Southwest China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure Southwest China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table Northwest China Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table Northwest China Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure Northwest China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure Northwest China Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table Northwest China Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table Northwest China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure Northwest China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure Northwest China Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Bristol-Myers Squibb
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb
-
Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb
-
Figure Revenue and Market Share Analysis of Bristol-Myers Squibb
-
Table Product and Service Introduction of Bristol-Myers Squibb
-
Table Company Profile and Development Status of Merck
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck
-
Figure Sales and Growth Rate Analysis of Merck
-
Figure Revenue and Market Share Analysis of Merck
-
Table Product and Service Introduction of Merck
-
Table Company Profile and Development Status of F Hoffmann-La Roche
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of F Hoffmann-La Roche
-
Figure Sales and Growth Rate Analysis of F Hoffmann-La Roche
-
Figure Revenue and Market Share Analysis of F Hoffmann-La Roche
-
Table Product and Service Introduction of F Hoffmann-La Roche
-
Table Company Profile and Development Status of Arbor Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Arbor Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of Arbor Pharmaceuticals
-
Figure Revenue and Market Share Analysis of Arbor Pharmaceuticals
-
Table Product and Service Introduction of Arbor Pharmaceuticals
-
Table Company Profile and Development Status of Eisai
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eisai
-
Figure Sales and Growth Rate Analysis of Eisai
-
Figure Revenue and Market Share Analysis of Eisai
-
Table Product and Service Introduction of Eisai
-
